Dimensional Fund Advisors LP Has $167.30 Million Position in Medpace Holdings, Inc. $MEDP

Dimensional Fund Advisors LP lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.0% during the first quarter, Holdings Channel.com reports. The institutional investor owned 348,485 shares of the company’s stock after selling 10,865 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Medpace were worth $167,300,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. NewEdge Advisors LLC increased its holdings in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC bought a new position in Medpace during the second quarter worth $296,000. Finally, M&T Bank Corp boosted its position in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $601.38 on Friday. The stock’s fifty day moving average price is $492.09 and its two-hundred day moving average price is $494.49. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The firm has a market cap of $17.18 billion, a price-to-earnings ratio of 35.25, a P/E/G ratio of 2.93 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the business earned $3.10 EPS. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MEDP. Robert W. Baird increased their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday. Truist Financial lifted their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday. BMO Capital Markets upped their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday. Royal Bank Of Canada increased their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $560.92.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.